A collection of 56 purified thrombin mutants, in which 76 charged or polar surface residues on thrombin were mutated to alanine, was used to identify key residues mediating the interactions of thrombin with thrombomodulin (TM), protein C, and thrombin-activatable fibrinolysis inhibitor (TAFI ). Three mutants (E25A, D51A, R89A/R93A/E94A) were found to have decreased ability to activate TAFI yet retained normal protein C activation, whereas three other mutants (R178A/R180A/D183A, E229A, R233A) had decreased ability to activate protein C but maintained normal TAFI activation. One mutant (W50A) displayed decreased activation of both substrates. Mapping of these functional residues on thrombin revealed that the 11 residues mediating the thrombin-TM interaction are all located in exosite I. Residues important in TAFI activation are located above the active-site cleft, whereas residues involved in protein C are located below the active-site cleft. In contrast to the extensive overlap of residues mediating TM binding and fibrinogen clotting, these data show that distinct domains in thrombin mediate its interactions with TM, protein C, and TAFI. These studies demonstrate that selective enzymatic properties of thrombin can be dissociated by site-directed mutagenesis.
Thrombin is unique among the clotting cascade serine proteases in its ability to interact with a large number of diverse substrates. These interactions can paradoxically lead to either procoagulant or anticoagulant effects. Procoagulant properties of thrombin include cleavage of fibrinogen to form a fibrin clot (1), activation of platelets through cleavage of the thrombin receptor(s) (2) , feedback activation of factors V, VIII, and XI (3, 4) , and activation of the transglutaminase, factor XIII (5). Binding of thrombin to the endothelial cell surface protein thrombomodulin (TM) 1 alters the substrate specificities of the enzyme, leading to loss of its procoagulant activities. The thrombin-TM complex acts as an anticoagulant through activation of protein C (PC), which attenuates the clotting cascade by inactivation of the activated cofactors V and VIII (6) . Additionally, thrombin activity can be regulated by several serine protease inhibitors, including antithrombin III, heparin cofactor II, and protease nexin I (7) (8) (9) . Recently, a new substrate for the thrombin-TM complex has been identified termed plasma procarboxypeptidase B or thrombin-activatable fibrinolysis inhibitor (TAFI) (10) . Activated TAFI functions as a fibrinolysis inhibitor by cleavage of C-terminal lysines from partially degraded fibrin, diminishing the activation of plasminogen, leading to delayed clot lysis (11) (12) (13) . Like PC, there is a 1,000-fold increase in the catalytic efficiency of TM-bound thrombin for TAFI activation compared with free thrombin. Unlike PC, TAFI is a metalloproteinase, has a short half-life, and has no identified specific plasma inhibitor, and the thrombin cleavage site in TAFI shares no homology to the site in PC. The thrombin domains involved in TAFI activation have not yet been identified.
Insights into the diverse specificities of thrombin have come from structural analysis of the crystallized molecule bound to either specific inhibitors (PPACK, hirudin) or substrate peptides (fibrinopeptide A, hirulog) (reviewed in Ref. 14) . The catalytic triad (His 43 , Asp 99 , Ser 205 ) 2 is located within a canyon-like cleft flanked by two major insertion loops, Leu (the Trp 50 loop) and Leu 144 -Gly 155 (the autolysis loop), that sterically restrict access to the active site. There are two patches of positively charged residues located on opposite sides of the active site termed exosite I and exosite II, and it is primarily these two domains that interact with the majority of substrates of thrombin and contribute to its exquisite specificity. Thrombin also contains a sodium-binding site, which is intimately involved in mediating allosteric changes within the molecule (15) . Sodium is coordinated by the carbonyl oxygen atoms of Arg 233 and Lys 236 , and the entire binding environment involves a charge-stabilizing system that includes Glu 229 , Glu 146 , Arg 197 , Asp 234 , and Tyr 237 . Functional studies into the contribution of these structural domains to the activities of thrombin have come from a variety of methodologies including the use of proteolyzed thrombin preparations (16, 17) , specific antibodies (18 -20) , peptide probes (2, 21, (23) (24) (25) , deletional or substitutional mutagenesis (26 -30) , naturally occurring thrombin mutants (31) (32) (33) (34) , and ion substitution (35) (36) (37) . We have previously described the approach of alanine-scanning mutagenesis, in which 79 highly exposed charged or polar residues on thrombin were individually mutated to alanine, and this library of mutants was screened for clotting activity, PC activation, and inhibition by antithrombin III (38, 39) . These studies demonstrated that all of these functional residues were located on one hemisphere of the molecule, which included the active site cleft and exosites I. Residues in which mutations caused changes in the procoagulant and anticoagulant activities of thrombin were not spatially distinct, but specific mutations that dissociated the clotting activity of thrombin from its PC anticoagulant activity were identified. This work led to the development of a novel class of anticoagulants, termed protein C activators, which have demonstrated in vivo anticoagulant (40, 41) and antithrombotic activity (42) .
To identify key residues in thrombin involved in TAFI activation, we decided to use the library of thrombin alanine mutants to compare the activation of the TM-dependent substrates PC and TAFI. Previous studies with the thrombin mutants used the strategy of transient expression of mutant prothrombin, activation by Echis carinatus venom, and thrombin quantitation by enzyme-linked immunosorbent assay. Although allowing for rapid screening, this strategy is limited by a number of factors, including obtaining limiting amounts of the mutants, the presence of venom in the media that can interfere in assays of the activities of thrombin, and accuracy/ reproducibility of the quantitation of enzyme concentration. To circumvent these problems, we have expressed these mutants in stable cell lines and purified them to homogeneity to have a collection of readily usable reagents that can broadly be used for structural-functional analyses of thrombin-substrate interactions. In the present study, we used this purified collection to identify thrombin residues involved in the activation of PC and TAFI. By using two TM-dependent substrates, we were able to distinguish residues important in the thrombin-TM interaction from those involved with the individual substrates. The results show that distinct domains in thrombin are involved in PC, TAFI, and TM binding and that PC and TAFI activation can be dissociated from each other.
EXPERIMENTAL PROCEDURES
Proteins and Reagents-Purified plasma protein C was from Hematologic Technologies (Burlington, VT). Purified fibrinogen was from Alexis Corp. (San Diego, CA). S-2238 (Phe-Pip-Arg-p-nitroanilide) and S-2366 (Glu-Pro-Arg-p-nitroanilide) were purchased from Chromogenix. 3-(2-Furyl)acryloyl-Ala-Arg-OH was from Bachem (Torrance, CA). Recombinant soluble TM (Solulin) and recombinant TAFI (43) were from Berlex Biosciences (Richmond, CA). Q-Sepharose Fast Flow was from Amersham Pharmacia Biotech, and Amberlite CG50 cation-exchange resin was from ICN Biomedicals. The detergent CHAPS, E. carinatus snake venom, QAE-Sephadex A-50, polyethylene glycol-8000, and N-glycanase were from Sigma. PPACK was from Calbiochem.
Construction and Expression of Mutant Prothrombins-The fulllength human prothrombin gene was inserted into the expression vector pRc/CMV (Invitrogen), and codons for 76 polar and charged surface residues were mutated to alanine by oligonucleotide-directed mutagenesis as described previously (38) . 56 purified plasmid DNAs (QIAGEN Maxi kit) encoding pRc/CMV-hPT mutants were linearized with ScaI, and 10 g of each was used to transfect 1 ϫ 10 6 CHO AA8 cells grown in a 35-mm well by the calcium phosphate method. CHO cells were grown and passaged in CHO S-serum-free medium (Life Technologies, Inc.) containing 10% fetal bovine serum and 100 units/ml penicillin and 100 g/ml streptomycin. Stable cells lines were obtained by limiting dilution and selection in G-418 (Life Technologies, Inc.). 12 colonies were randomly selected for each mutant, expanded to confluence in a 35-mm well, and tested for prothrombin secretion by incubation of the washed monolayer with 1 ml of serum-free CHO media for 24 h at 37°C or 30°C. Mutant prothrombins (100 l of conditioned media) were processed to thrombin with 5 g of Echis venom at 37°C for 1 h and assayed for thrombin activity with S-2238. Two or three of the clones with the highest expression were kept and expanded into roller bottles.
For each mutant, 6 -10 roller bottles were grown to confluence, washed extensively with phosphate-buffered saline, and then incubated with serum-free medium. Conditioned medium was harvested every 5-7 days.
Purification of Thrombin Mutants-The purification procedures for prothrombin and thrombin were modified from previously described protocols (41) . For each mutant, ϳ2 liters of conditioned medium containing 7-50 mg of crude prothrombin, was batch-extracted with 50 ml of swollen QAE-Sephadex (equivalent to 2.5 g of dry resin) for 1 h at room temperature. The resin was collected on a glass-sintered funnel, and prothrombin was eluted immediately by the addition of 50 ml of 20 mM HEPES, pH 8.0, 2 M NaCl for 15-30 min. After centrifugation, the supernatant was collected and dialyzed against 0.1 M potassium phosphate, pH 7.5. The dialysate was loaded onto a Q-Sepharose fast flow column (10 ml) and washed, and prothrombin was eluted with a 0.1-0.7 M potassium phosphate, pH 7.5, gradient. Fractions were activated with Echis venom and tested for amidolytic activity. Peak fractions were pooled and dialyzed against 20 mM HEPES, pH 8.0, and 0.1 M NaCl. 25 ml of mutant prothrombin was processed to thrombin with 1 mg of Echis venom that had been preincubated with Amberlite CG50. After incubation for 45 min at 37°C, the thrombin mutant was loaded directly onto an Amberlite CG50 column (10 ml) equilibrated in 20 mM HEPES, pH 8.0, and washed, and thrombin was eluted with a 0.1-1.0 M NaCl gradient. Fractions were assayed for amidolytic activity, pooled, and dialyzed against 10 mM potassium phosphate, pH 7.4, 150 mM NaCl, and 0.1% polyethylene glycol-8000. After dialysis, the thrombin was concentrated with a Centriprep-10 (Amicon), and concentration was determined by A 280 using an extinction coefficient (0.1%) of 1.83.
Steady-state Kinetics of S-2238
Hydrolysis-The initial rates of S-2238 hydrolysis, monitored by an absorbance change at 405 nm (SpectraMAX, Molecular Devices), were measured for each of the mutants using 2 nM purified mutant with 2, 4, 6, 8, 10, 15, 20, 25, 50, 100, and 150 M substrate in 20 mM Tris, pH 8.3, 150 mM NaCl. K m and k cat were determined by fitting the data to the Michaelis-Menton equation.
Fibrinogen Clotting-Fibrinogen clotting activity was determined for each of the mutants by using a purified fibrinogen solution and measuring the time to clot formation with a fibrometer. 150 g of fibrinogen in 290 l of Dulbecco's phosphate-buffered saline with calcium and magnesium (Irvine Scientific, Santa Ana, CA) was incubated at 37°C for 5 min. Clotting was initiated by the addition of 10 l of thrombin mutant. A standard curve with wild-type (WT) thrombin ranging from 8.3 nM to 50 nM was used to convert clotting times of the mutants to nM equivalents of WT thrombin. Mutants were tested initially at 16.7 and 33.3 nM in duplicate. For those mutants with diminished clotting activity, increasing amounts were used to give at least 2 points within the standard curve (range: 25-75 s).
Protein C Activation-Activation of PC was carried out in 20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM CaCl 2 , 0.2% CHAPS in the presence and absence of 50 nM soluble TM. In the presence of TM, 3 nM mutant thrombin was incubated with TM at room temperature for 5 min. PC was added at a final concentration of 200 nM and incubated for 60 min at 37°C. The reaction was terminated by the addition of 10 M PPACK, and PC activity was determined by hydrolysis of the substrate S-2366. In separate experiments, PPACK at this concentration had no effect on the cleavage of S-2366 by activated PC yet fully inhibited thrombin activity. A standard curve with WT thrombin ranging from 0.25-16 nM was constructed for each experiment to convert mutant activity to wild-type equivalent. For mutants with Ͻ15% WT activity, increasing amounts were used to give at least two points within the standard curve. In the absence of TM, PC activation was carried out in the same buffer, but 100 nM mutant thrombin was incubated with 1 M PC at 37°C for 2 h. The WT standard curve ranged from 25-400 nM thrombin.
TAFI Activation-Activation of TAFI was carried out in the same buffer as for PC. 100 pM mutant thrombin was incubated with 50 nM TM for 5 min at room temperature. Then recombinant TAFI was added at a final concentration of 85 nM and incubated for 20 min at room temperature. The reaction was terminated by the addition of 5 M PPACK, and TAFI activity was determined from the initial rate of hydrolysis of the substrate 3-(2-furyl)acryloyl-Ala-Arg-OH (final concentration 600 M) at 37°C by monitoring the absorbance change at 336 nM (44) . A WT standard curve ranging from 15.6 -1000 pM thrombin was constructed for each experiment to convert mutant activity to WT equivalent. For mutants with Ͻ15% WT activity, increasing amounts were used to obtain at least two points within the standard curve.
RESULTS
Expression, Amidolytic Activity, and Clotting Activity of Thrombin Mutants-In the previous studies employing this large collection of thrombin alanine mutants, a strategy of transient transfection in COS-7 cells followed by concentration, activation, and quantitation was undertaken to study a number of the enzymatic activities of thrombin (38, 39) . In the present study, we have successfully converted the collection of mutants to purified preparations (Table I) . Permanent CHO cell lines were established for each of the 56 mutant prothrombins, and crude prothrombin was obtained for all of them except one mutant, N53A/T55A, which is the site of N-linked glycosylation in the protein. It is possible that mutation of this site leads to inefficient secretion by the CHO cells. All of the remaining mutants were successfully processed to ␣-thrombin with Echis venom and purified to 95% homogeneity (Fig. 1A) , with the exception of one mutant, E202A. Although initially processed correctly, after cation-exchange purification and dialysis, this preparation consistently and repeatedly degraded to a lower molecular weight form. The glutamate 202 resides in the S3 specificity pocket of the active site, and mutation to alanine may convert thrombin to a "trypsin-like" enzyme, ,500 by SDS-polyacrylamide gel electrophoresis, with the upper band comigrating with plasma-purified thrombin. Digestion of these proteins with N-glycanase resulted in a single sharp band of identical mobility to digested plasma-purified thrombin, suggesting that there is heterogeneity in the glycosylation of the recombinantly expressed proteins (Fig. 1B) . The catalytic efficiency of S-2238 hydrolysis was determined for each of the mutants (Table I) and was found to be comparable to WT except for 2 mutants, W50A and E229A, which were reduced 5-10-fold compared with WT. In the fibrinogen clotting assay, 16 of the mutants had less than 50% WT activity, with 7 of these Ͻ15% (Table I) . These results are similar to those obtained previously with transient transfection in COS-7 cells (38, 39) .
Protein C and TAFI Activation by Thrombin Mutants-All 56 mutants were screened for activation of PC and TAFI in the presence of soluble TM (Fig. 2) . Activation of these substrates was carried out under identical buffer conditions and similar substrate concentrations for direct comparison. The majority of the mutants displayed wild-type activity, with no effect on either PC or TAFI activation. 12 mutants showed less than 50% WT activity in activation of both substrates: K21A, Q24A, W50A, R62A, K65A, H66A, R68A, T69A, Y71A, R73A, K77A, and K106A. All of these residues except Trp 50 are located in exosite I. These effects are not due to generalized disruption of the molecule, because all of the mutants (except W50A) have WT catalytic efficiency for S-2238 cleavage; in addition, the Q24A mutant has WT clotting activity. Interestingly, mutants were identified with selective effects on the two substrates. Three mutants, E25A, D51A, and the triple mutant R89A/ R93A/E94A, showed diminished TAFI activation but maintained WT PC activation, whereas three others, R178A/R180A/ D183A, E229A, and R233A, showed WT TAFI activation but diminished PC activation. These residues are candidates for those that are important in the activation of the individual substrates.
Protein C Activation in the Absence of TM-Activation of the substrates PC and TAFI by thrombin-TM requires formation of a ternary complex. Thrombin mutations that affect activation of both substrates may do so simply by disrupting the thrombin-TM interaction, thereby preventing complex formation. To determine which residues may be involved in the thrombin-TM interaction, the activation of PC in the presence and absence of TM was determined for the 56 thrombin mutants (Fig. 3) . Those mutants that display diminished activation of PC in the presence of TM but normal activation in the absence of TM are likely to mediate binding of TM to thrombin. Activation of PC was carried out under identical buffer conditions for direct comparison. Again, the majority of mutants displayed WT activity, having no effect on PC activation in the absence or presence of TM. Three mutants (R20A, S22A/Q24A/E25A, E25A) were identified with enhanced activation of PC in the absence of TM, showing a 2.6 -3-fold enhancement in activation. Of the 15 mutants with diminished PC activation in the presence of TM, 11 displayed normal or elevated basal activation in the absence of TM (K21A, Q24A, R62A, K65A, H66A, R68A, T69A, Y71A, R73A, K77A, K106A) (Fig. 4) . These mutations are all located in exosite I, supporting the hypothesis that these residues are involved in interactions with TM. Four mutants (W50A, R178A/R180A/D183A, E229A, R233A) showed decreased PC activation in both the presence and absence of TM, suggesting these mutations affect direct interactions with PC (Fig. 4) , and only one of these, W50A, demonstrated defective TAFI activation, suggesting that this is the only site of overlap on thrombin for these two substrates.
Localization of the PC-, TAFI-, and TM-interacting Residues on Thrombin-Mapping of the functional residues involved in PC and TAFI activation demonstrates that discrete domains in the molecule are involved (Fig. 5) . Residues involved in the thrombin-TM interaction localize exclusively to the exosite I domain, are primarily positively charged, and overlap significantly with those residues important in fibrinogen clotting. Residues mediating TAFI interaction are located along the "rim" above the active site and are primarily negatively charged. Residues important in PC activation are located along the rim below the active site and are intimately involved in the sodium binding pocket. Trp 50 is the only identified residue that is involved with both substrates but not involved directly in the thrombin-TM interaction.
DISCUSSION
This study describes the use of a large collection of thrombin mutants to identify key residues involved in the interaction of thrombin with thrombomodulin, protein C, and TAFI. This stategy of alanine scanning has been described previously (38, 39) , in which 79 charged or polar surface residues on thrombin have been systematically mutated to alanine to minimize nonspecific structural pertubations in the molecule while focusing on those residues most likely to mediate the interactions of thrombin with macromolecular substrates. These residues cover 62% of the solvent-accessible surface of the molecule, allowing for a comprehensive structural-functional analysis of the molecule. To obtain a readily usable set of reagents in sufficient quantity for detailed studies, the library of mutants was converted into purified thrombin preparations. The thrombin mutants used here were purified after expression in CHO cells and have similar enzymatic and clotting activities to those of transiently expressed thrombins in crude cell supernatants used in earlier studies. Despite the heterogeneity in glycosylation of the proteins, there was no evidence for any significant effects on the enzymatic properties of thrombin when produced in CHO cells rather than COS-7 cells.
By comparing the activation of two thrombin-TM-dependent substrates, we were able to identify specific domains on thrombin mediating its interaction with each of these molecules. Mutations in thrombin were found that either had selective effects on PC activation, TAFI activation, or both. Those mutations affecting both substrates were found to do so primarily Mutants that showed significantly reduced PC activation only in the presence of TM were designated as TM-interacting residues, whereas those that showed reduced activity either in the presence or absence of TM were designated as PC-interacting residues.
by disruption of the thrombin-TM interaction, and all of these residues are located in exosite I. In the previous study (38) , only two residues (Arg 70 , Gln 24 ) were identified that had normalized PC activation in the absence of TM compared with 11 residues in the current study. This difference is most likely due to differences in the assay conditions. In the original study, PC activation without TM was carried out in the absence of calcium and compared with activation with TM in the presence of calcium. Calcium has been shown to have direct effects on PC activation (45) , so that a direct comparison of thrombin mutant PC activation under different buffer conditions could be misleading. In the current study, PC activation was determined under identical buffer conditions. In addition, we found only a minor effect for the R70A mutant on PC activation (ϳ50% WT activity), which differs from the previous study. There may be differences between the soluble TM used in this study and the full-length membrane-bound form used previously (38) , although a recent study suggests that there is little difference in TAFI activation between these two forms of TM (46) . The current PC activation results have been repeated using a second preparation of R70A, and the presence of the R70A mutation in the purified protein was confirmed by using Lys-C digestion followed by mass spectroscopy of the thrombin fragments (data not shown). This residue was also studied by Wu et al. (26) , who found more profound effects, but these may be attributed in part to the mutant used in their studies, R70E, which involves a charge reversal that could have more dramatic effects on thrombin-TM binding.
Enhanced activation of PC by thrombin in the presence of TM is postulated to occur by formation of a ternary complex, which could lead to either conformational changes in thrombin, which change its substrate specificity (7), or changes in PC, which make it a better substrate for thrombin (47) . Mutations in thrombin could interfere with formation of the thrombin-TM complex, could affect its ability to undergo the allosteric changes needed for proper substrate activation, or could directly affect interactions with PC. In this communication, we have used the panel of purified thrombin mutants as a general screen to identify interesting residues involved in TAFI and PC activation for future studies.
Enhanced PC activation in the absence of TM has been described previously for two thrombin mutants, E25K and E202Q (28, 29) , which has led to the hypothesis that there are repulsive interactions between thrombin and the PЈ3 and P3 aspartate residues in PC, making PC a poor substrate for free thrombin. We confirmed this finding for the E25A mutant and observed the same effect for R20A. This is not completely unexpected, as Arg 20 is hydrogen-bonded with Glu
25
, and mutation of either residue would disrupt this interaction (29) . Because of autodegradation, E202A could not be produced and tested in this system. Whether or not a similar mechanism for TAFI activation exists remains to be tested. The P3 and PЈ3 residues of TAFI are not acidic (NDTVSPRASAYY), and in the absence of TM, thrombin will cleave at additional sites leading to TAFI inactivation. Furthermore, mutation of acidic residues in thrombin (Glu 25 , Asp 51 , and possibly Glu 94 ) diminishes TAFI activation, suggesting there may be important basic residues in TAFI mediating the thrombin interaction. Further studies will be necessary to elucidate the mechanism for enhanced TAFI activation with TM.
Although mapping of the residues important in fibrinogen clotting and PC activation (with TM) showed considerable overlap in the molecule, those involved in PC and TAFI activation show that distinct domains are involved. The residues important in TAFI activation lie above the active site, involving and in close proximity to the Trp 50 insertion loop. Trp 50 itself appears to be a critical residue for all of the activities of thrombin, as mutation or deletion of this residue results in diminished small molecule substrate hydrolysis, fibrinogen cleavage, PC activation, and antithrombin III inhibition. This is unlikely to be due to nonspecific stuctural pertubations within the loop, as mutations of neighboring residues have very selective effects; D51A has normal clotting activity and PC activation but diminished TAFI activation, whereas K52A has diminished clotting activity but normal PC and TAFI activation. The residues important in PC activation are below the active site and clustered around the sodium binding pocket. Mutation of these residues may lead to allosteric changes in thrombin affecting PC activation, or alternatively, represent residues in direct contact with the substrate, which then affects sodium binding. In either case, these residues are not involved in TAFI activation.
Previous studies with EGF deletion mutants (48, 49) have demonstrated the functional TM requirements for enhanced PC and TAFI activation. EGF5-6 of TM binds with high affinity to thrombin but does not enhance PC activation, whereas EGF i4 -6 supports enhanced PC but not TAFI activation. EGF3-6 supports both enhanced PC and TAFI activation, but deletion of EGF4 alone (to give EGF35-6) does not support activation of either TAFI or PC. These data, taken together with the current thrombin mapping data, suggests one possible model for formation of the ternary complexes. Namely, EGF5-6 would mediate the binding of TM to thrombin exosite I and orient EGF4 and EGF3 such that they are adjacent to the lower and upper lips of the active-site cleft, respectively. EGF4 would then align PC along the lower cleft, where it could interact with the residues around the sodium binding pocket, which is located on the opposite side of the molecule from exosite I. This assembly process is further augmented by the endothelial cell PC receptor (50) , and the current mapping data suggest that thrombin and PC would be bridged on opposite sides by TM and the endothelial PC receptor in a quaternary complex. On the other hand, EGF3 would align TAFI along the upper lip to contact the acidic residues in and around the Trp 50 loop. Although perhaps overly simplistic, this model could be tested directly using TM alanine mutants in conjunction with the thrombin alanine mutants or TAFI mutants to map potential sites of interaction between all of these molecules. In addition, the thrombin mutant data along with the TM deletion data strongly suggest that the mechanisms of activation of TAFI and PC by the thrombin-TM complex are quite different.
In summary, a large collection of purified thrombin alanine mutants was used to map the interaction of thrombin with TM, PC, and TAFI. These studies demonstrated that specific mutations can dissociate PC from TAFI activation in the presence of TM. This library represents a powerful set of reagents for studying the numerous macromolecular interactions of thrombin. By examining the functional requirements for a particular thrombin activity, one may identify candidate residues that effectively dissociate one thrombin activity from another. Since knock-out of the prothrombin gene in mice results in either embryonic lethality or death soon after birth from hemorrhage (22, 51) , introduction of (pro)thrombin mutants with selected deficient activities might allow one to salvage these mice and examine the interplay of the numerous and complex macromolecular interactions of thrombin in vivo.
